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The function of miR-143, miR-145 and the MiR-143 host gene in
cardiovascular development and disease
Francesca Vacantea, Laura Denbya, Judith C. Sluimera,b, Andrew H. Bakera,⁎
a Centre for Cardiovascular Science, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK
bMaastricht University Medical Centre, Dept. of Pathology, Maastricht 6229 HX, The Netherlands
A B S T R A C T
Noncoding RNAs (long noncoding RNAs and small RNAs) are emerging as critical modulators of phenotypic changes associated with physiological and pathological
contexts in a variety of cardiovascular diseases (CVDs). Although it has been well established that hereditable genetic alterations and exposure to risk factors are
crucial in the development of CVDs, other critical regulators of cell function impact on disease processes. Here we discuss noncoding RNAs have only recently been
identified as key players involved in the progression of disease. In particular, we discuss micro RNA (miR)-143/145 since they represent one of the most characterised
microRNA clusters regulating smooth muscle cell (SMC) differentiation and phenotypic switch in response to vascular injury and remodelling. MiR143HG is a well
conserved long noncoding RNA (lncRNA), which is the host gene for miR-143/145 and recently implicated in cardiac specification during heart development.
Although the lncRNA-miRNA interactions have not been completely characterised, their crosstalk is now beginning to emerge and likely requires further research
focus. In this review we give an overview of the biology of the genomic axis that is miR-143/145 and MiR143HG, focusing on their important functional role(s) in the
cardiovascular system.
1. Introduction
In mammalian cells, > 90% of transcripts are now known to code
for a vast repertoire of noncoding RNAs, which range from ~22 nt
(short noncoding RNAs) to long noncoding transcripts> 200 nt in
length [1,2]. Many studies have contributed to unravelling the com-
plexity of the regulatory networks involving noncoding RNAs [3], and
this is becoming an area of great interest to the field. However, their
mechanistic role in regulating gene expression programs and their in-
volvement in physiological and pathological conditions is still in-
completely known and requires improved knowledge. This is particular
relevant for cardiovascular development, homeostasis and disease
context. To date, microRNAs represent the most studied class of small
noncoding RNAs with well characterised biological function and a
single mode of action [4]. Notably, many microRNA expression patterns
have been associated with several human diseases, thus suggesting their
influence in the cellular response to pathological stress [5]. How
miRNAs are regulated, is however, a more complex question, as this can
occur at the transcriptional and post-transcriptional level [6]. Recently,
the crosstalk between miRNAs and long noncoding RNA (lncRNA) has
attracted increasing attention leading to the identification of new reg-
ulatory networks (reviewed by Ballantyne et al. and Yoon et al. [7,8]).
An example of such cross-talk is the interaction between lncRNA
MiR143HG and miR-143/145; the focus of this review. Mir-143/145 is
a vascular-enriched miRNA cluster, fairly extensively studied in vas-
cular biology and in the pathophysiology of cardiovascular disease
[9–13]. This microRNA cluster was shown to be encoded in a bicistronic
unit [13] located downstream of the lncRNA MiR143HG, host gene of
the miR-143 miRNA. Notably, the structure, the expression and the
function of lncRNAs has gained increasing attention, resulting in rapid
progression in the understanding of their potential importance [14,15].
The effort that has been dedicated toward the understanding of
lncRNA biology and their characterisation, resulted in a more accurate
genomic annotation, subcellular compartmentalisation, structural and
mechanistic roles in physiological and pathological contexts thus re-
vealing their functional heterogeneity. The eukaryotic ncRNA world is
conventionally divided into two groups of transcripts based on the
length of their sequence [2]: many of them are processed into small
ncRNAs (< 200 nt) including microRNAs, transcription initiation RNAs
(tiRNAs), Piwi-interacting RNAs (piRNAs), small nuclear RNAs
(snoRNAs), small interfering RNAs (endogenous siRNAs) [16]. The
second group of ncRNA transcripts is represented by long ncRNAs,
comprising transcripts longer then 200 nt in their mature form [17], of
which only a small fraction have been characterised mechanistically to
date.
https://doi.org/10.1016/j.vph.2018.11.006
Received 1 June 2018; Received in revised form 22 November 2018; Accepted 22 November 2018
⁎ Corresponding author.
E-mail address: Andy.Baker@ed.ac.uk (A.H. Baker).
Vascular Pharmacology xxx (xxxx) xxx–xxx
1537-1891/ © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
Please cite this article as: Vacante, F., Vascular Pharmacology, https://doi.org/10.1016/j.vph.2018.11.006
2. MicroRNA biogenesis
MicroRNAs are negative regulators of gene expression at the post
transcriptional level [18]. Their biogenesis is a two-step process which
starts in the nucleus with the transcription of a pri-microRNA guided by
RNA polymerase II or III, and ending in the cytoplasm (reviewed by
Krol et al. and Davis-Dusenbery et al.) [19,20]. The primary transcript,
originating in the nuclear compartment, is cleaved by RNAseIII
(Drosha) to produce the precursor miRNA (pre-miRNA), and subse-
quently transported into the cytoplasm where it is processed by a spe-
cific endonuclease (Dicer) [21]. The result is a double-stranded RNA
(guide and passenger strand), which is then integrated into the RNA-
induced silencing complex (RISC). One strand is usually degraded, and
the other strand will guide the RISC complex to the mRNA target.
However, exceptions to this phenomenon are known. For example the
passenger strand of the stem loop may be functional, as observed with
let-7 family members [22] and miR-126 [23]. A specific sequence of the
mature miRNA, called the seed sequence, is essential to recognise and
bind the mRNA target, usually - but not exclusively- in its 3′ un-
translated region (3’UTR). This phenomenon results in a negative reg-
ulation of gene expression by translational inhibition or destabilization
and degradation of the mRNA target molecule [18].
3. LncRNA biology and function
Long noncoding RNAs (lncRNAs) are a large family of ncRNAs
commonly described as transcripts longer than 200 nt with limited or
no open reading frame (ORFs) [24]. This relatively new class of tran-
scripts was initially identified by large-scale sequencing of cDNA li-
braries in mouse [25]. Although the function of only 10% of the already
annotated lncRNAs has been identified, the number of newly identified
lncRNAs continues to rise with advances in techniques to characterise
their structure and associated bioinformatical tools that are available
[26]. Similar to protein-coding genes, lncRNAs are transcribed by RNA
Polymerase II or III followed by modifications associated with capping,
splicing, histone modifications and in some cases polyadenylation [27].
Notably, while they generally show low conservation levels of their
primary sequence [28], the promoter of some lncRNAs was found to be
more highly preserved across species [27]. Remarkably, even though
the structure of relatively few lncRNAs have been described to date
[29,30], it is becoming clear that lncRNAs often fold into thermo-
dynamically stable structures. This knowledge may be instrumental in
characterizing their function [31]. Different sub-groups of lncRNAs
have been described based on their genomic location and orientation:
sense, antisense, bidirectional, intronic, intergenic (lincRNA) and cir-
cular lncRNAs [32]. At a molecular level, the capability of interacting
with multiple partners, such as RNA, DNA, or protein, endows them
with several complex biological functions based on their subcellular
localisation (reviewed by Ponting et al. and Ulitsky et al.) [15,33].
Particularly, their subcellular localisation now appears strictly con-
nected to their functional role in modulating cellular processes (Fig. 1)
[34]. Importantly, some of them have recently been described to have
specific RNA-binding motives, critical for their nuclear localisation and
the regulation of gene expression [35]. Nonetheless, one of the main
features of lncRNA molecules is their cell- and temporal-specific ex-
pression profile, which can be modulated in response to physiological
or pathological cues [36,37]. Moreover, the modulation of lncRNA
expression in specific pathological contexts and the involvement of
these molecules in cell-cell communication, has raised interest in in-
vestigating their potential role as biomarkers during vascular injury
[38]. Deep sequencing and comparison between different pathological
states has revealed profound changes in the expression of ncRNAs, in-
dicating their role and involvement in the pathophysiology of disease.
Therefore, deciphering their molecular mechanism of action in both,
physiological and pathological contexts, might open new possibilities of
therapeutic interventions.
In the nucleus, lncRNAs can modulate gene expression by enhancing
or repressing the transcription of specific genomic loci by recruiting
chromatin modifying complexes or inhibiting the binding of tran-
scriptional factors to their DNA targets [39]. They can also modulate
the splicing process by inducing or inhibiting the abundance of specific
transcripts [14]. In the cytoplasm they can modulate gene expression at
post-transcriptional level, interacting with proteins or other ncRNAs
(microRNAs and mRNAs). Many lncRNA seem to act as scaffold for the
assembling of proteins involved in same molecular networks [40].
Some of them can also regulate the processing of their mRNA including
translation and degradation [41]. LncRNA can act as molecular sponges
for microRNAs thus limiting their capability to bind their targets.
LncRNA can also encode short functional peptides called (micropep-
tides) [42]. Recentely, lncRNA have also been described as important
players of cell-cell communication being secreted in the extracellular
environment by extracellular vesicles [43].
Collectively, there is wealth of known and evolving data supporting
the substantial influence that miRNA and lncRNA possess. In this re-
view, we bring this together and focus on the biology and function of
the lncRNA host gene of miR-143, miR-143HG and the miRNAs miR-
143 and miR-145 and review their known roles in the cardiovascular
system. We further highlight particular areas that we believe are im-
portant to assess in the future.
4. The biology of the miR-143/145-MiR143HG axis
4.1. miR-143/145 in vascular cell biology
MiR-143 and miR-145 are among the best characterised small reg-
ulatory ncRNAs in the vasculature. The underpinning biogenesis and
processing of the miR-143/145 cluster has been extensively studied by
different research groups [4,20,44]. Collectively, these findings show
that miR-143/145 are co-transcribed from a single bicistronic unit,
localised on human chromosome (chr) 5 and on murine chr18
(GRCh38) to an individual pri-microRNA transcript. Therefore miR-
143/145 share regulatory elements of their expression [9,10]. Studies
on sequence conservation have revealed the presence of a highly con-
served region (4.2 kb) of the promoter of the miR-143/145 cluster,
containing binding sites for transcriptional factors regulating vascular
smooth muscle cell (vSMC) contractility. Particularly, the serum re-
sponse factor (SRF)/myocardin (Myocd) complex is a potent activator
of vSMC differentiation (Fig. 2) [45]. Upon binding of the CArG-box on
the miR-143/145 promoter, the SRF/Myocd axis induces tissue-specific
microRNA expression in the heart and the vasculature [10,13] [11]. In
addition to the SRF/Myocd pathways, the regulation of the miR-143/
145 expression is controlled by transforming growth factor β 1 (TGF-
β1)/bone morphogen protein 4 (BMP4) network [46,47]. This family of
growth factors induces the transcription of genes associated to the
vSMC contractile phenotype including the miR-143/145 expression,
which in turn represses the expression of genes associated with vSMC
phenotypic switch [11]. However, Boettger et al. identified angiotensin-
converter enzyme (ACE) as a critical regulator of vSMC contractility
and as a putative target modulated by miR143/145-mediated transla-
tion repression [48]. Likewise, Jag-1/Notch, a known regulatory
pathway of vSMC phenotype [49] was described as a positive regulator
of miR143/145 expression. This pathways seems to act independently
from SRF/Myocardin, thereby amplifying the vSMC differentiation
signals [50]. Boettger et al. and Elia et al. studied the miR-143/145
expression profile at different stages of mouse embryonic development
[48,51]. In both studies, miR-143/145 was found to be highly ex-
pressed in the heart at early stage of embryogenesis (E9-E16) while,
postnatally, the expression of miR-143/145 strongly correlates with
vSMC in the aorta and coronary vessels [48,51,52]. This dynamic ex-
pression might allow the proliferation and maturation necessary during
embryogenesis, once a vSMC signature is established in early devel-
opment (Fig. 2). Although miR-143 and miR-145 are co-transcribed in a
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bicistronic primary transcript, studies have demonstrated the absence
of homology in their mature sequence, indicating their capability to
bind and regulate different targets [12]. For instance, miR-145, but not
miR-143, was described to play a key role in controlling embryonic
stem cells (ESC) differentiation, by directly repressing critical plur-
ipotency factors: OCT4, SOX2, KLF4 [53]. Moreover, studies on heart
morphogenesis in zebrafish, demonstrated the importance of miR-143
as intrinsic factor involved in the cardiac development, whereas mir-
145 did not show a similar function. Particularly, in vivo knockdown
(KD) of miR-143 in zebrafish, showed that miR-143 acts as a critical
regulator of myocardial cell growth and elongation by directly targeting
Adducin3 (Add3) protein which blocks actin filaments rearrangement
[54]. Moreover, miR-143 KD caused myocardial abnormalities in atrial
and ventricular structure and defects in heart function [55]. Bioinfor-
matic approaches and in vitro experiments performed in human and
mouse vSMCs identified two transcriptional factors, ETS domain-con-
taining protein (Elk1) and Myocd, as direct targets for miR-143 and
miR-145 respectively. Particularly, Elk1, myogenic repressor and in-
ductor of vSMC proliferation [56], was found to be transcriptionally
downregulated by miR-143 and upregulated in the presence of an an-
tagomir for miR-143 in vSMCs [13]. On the other hand, miR-145 is
important for the maintenance of vSMC phenotype by increasing the
levels of Myocd which in turn induces vSMC differentiation and con-
tractility [13]. Furthermore, binding sites for miR-145 were found in
the 3’ UTR of Kruppel-like factor 4 (Klf4), positive regulator of vSMC
proliferation and phenotypic switch.
Interestingly, despite the lack of clear sequence homology, the two
microRNAs were also described to target common genes and pathways
such as Slit-Robo GTPase-activating protein 1 and 2 (Srgap1 and 2) and
Sling-shot 2 (Ssh2) involved in the regulation of F-actin polymerization
and depolymerization, cell migration and cytoskeleton remodelling
[12]. Importantly, these studies reveal complex regulatory networks in
which miR-143 and miR145 can act synergistically in the reinforcement
of vSMC contractile phenotype by independently targeting different
molecular pathways.
4.2. miR143/145 in cardiovascular disease (CVD) pathogenesis
Since miR-143/145 are critical in the maintenance of vSMC con-
tractility and differentiation, here we describe their role in vSMC-driven
pathologies, such as hypertension, atherosclerosis, and pulmonary ar-
terial hypertension (PAH). Several studies have interrogated their in-
volvement in modulating the vSMC response to vascular injury
[9,10,13,49,51] [58,59]. Neointima formation is one of the main pro-
cesses underlying vascular remodelling following vascular damage
[60]. In vivo studies using miR-143 and miR-145 double KO mice re-
ported that in the KO animals had formation of neointimal lesions in the
femoral artery compared to wild type animals, even in the absence of
injury. This suggests the critical role of these microRNAs in controlling
the vSMC phenotypic switch during vascular injury [48]. In line with
these results, miR-143 and miR-145 were found to be dramatically
downregulated in the carotid artery of balloon-injured rats, where
proliferative and dysregulated vSMC contribute to the lesion develop-
ment [58]. In addition, adenovirus-mediated overexpression of the
miR-145 stem-loop inhibited the formation of neointima in balloon-
injured arteries [52]. Moreover, lentivirus-mediated overexpression of
miR-145 in Apoliprotein E (ApoE−/−) KO mice was found to reduce
atherosclerotic plaque size and induce a more stable plaque phenotype,
as indicated by a significant increase in the fibrous cap area and plaque
collagen content, and to decrease in the number of pro-inflammatory
macrophages populating the plaque [61]. In contrast, in human, the
miR-143/145 cluster was significantly upregulated in advanced and
symptomatic atherosclerotic plaques compared to asymptomatic con-
trols, probably indicating the dynamic expression of the microRNA
cluster during the late stages of the pathology progression [62].
In contrast to the reduction in expression of miR-143 and miR-145
commonly observed in the peripheral vascular system in response to
injury, miR-143 and miR-145 were found to be upregulated in a hy-
poxia-induced mouse model of PAH and in human clinical samples
versus healthy controls. This suggest these miRNAs affect the patho-
physiology of PAH via increased expression. Consistent with this no-
tion, anti-miR-mediated knockdown of miR-145 in mouse resulted in a
Fig. 1. Long noncoding RNA function.
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protective effect from the development of PAH. Consistent with these
results, miR-145 was found upregulated in arterial SMCs of patients
affected by idiopathic and familiar PAH versus controls, thus con-
firming the involvement of the microRNA in the pathophysiology of
PAH vascular remodelling [9]. Importantly, further in vivo and in vitro
studies interrogating the role of miR-143 during the development of
PAH, showed that miR-143 was selectively upregulated during pul-
monary arterial smooth muscle cell (PASMC) migration. Moreover, the
modulation of miR-143 altered the migratory capability and apoptotic
rate of PASMCs and, remarkably, the genetic ablation of miR-143 al-
leviated the development of PAH in vivo [10].
Collectively, these studies demonstrate that both miR-143 and miR-
145 have important functions in diverse vascular beds, that their ex-
pression can be regulated in either direction in response to diverse in-
jury stressors and that intervention to modulate levels of these miRNAs
is often therapeutic.
4.3. miR143/145 as biomarkers of CVD
MiRNAs have also been proposed as potential biomarker for cardi-
ovascular diseases since their dysregulation in pathological stress con-
ditions is quite clear, and miRNA are often released from cells and
tissues in response to injury. With this in mind, circulating miR-145 was
found upregulated in the plasma of patients with unstable versus stable
angina [57,59]. Importantly, it was reported by several studies that
extracellular vesicles are carriers of ncRNAs in cardiovascular disease
[63,64]. In this context, miR-143 was identified as a potential paracrine
mediator of cell-cell communication between SMC endothelial cells
(ECs) during vascular remodelling in PAH [10]. Importantly, the SMC-
EC signalling carried out by miR-143/145 in extracellular vesicles, was
described as atheroprotective in ApoE−/− mice as it contributed to the
reduction of plaque development [65]. The transfer of miR-143/145
was described to be mediated not only by extracellular vesicles, but also
by membrane protrusions between SMCs and ECs. These findings were
confirmed by in vitro and in vivo approaches which showed that, once
being transferred from SMCs, miR-143 and miR-145 were able to
modulate EC angiogenesis and proliferation by directly binding hex-
okinase II and integrin β 8 respectively [46]. Collectively, these results
advanced the knowledge of the complex regulatory circuits involving
miR-143 and miR-145, defining their involvement as modulators of
vSMC phenotype in physiological conditions and vascular disease.
Therefore, the molecular mechanisms regulating their expression may
be a suitable target for therapeutic approaches. It will be critical,
however, to ensure selective modulation of these miRNAs in the target
tissue, since widespread modulation of these miRNAs might evoke
unacceptable side effects.
Schematic illustration of the main pathways regulated by miR-143/
145 in vSMCs. During development, miR-143/145 show high expres-
sion levels in the myocardium of mouse embryo (E7-E9). In late car-
diogenesis, expression mainly correlates with the ventricles and atria
(E15). The expression pattern is then inverted post-natally, where miR-
143/145 is expressed only in the aorta and pulmonary arteries. In
physiological conditions in adult mouse, the vascular-specific
microRNA cluster controls the transcription of contractility and differ-
entiation genes typical of a SMC signature (α-SMA, Calponin, Mhy11).
Particularly, the transcriptional regulation of vSMC contractile pheno-
type involves binding of SRF/Myocd (Serum Responsive Factor/
Myocardin) to the CArG box located on the promoter of contractility
genes, which in turn induce the miR-143/145 expression. Importantly,
miR-143/145 is also implicated in the regulation of the vSMCs phe-
notypic switch in vascular disease. Particularly, miR-143/145 was
found dysregulated in response to vascular injury, such as hypoxia,
stretch, shear stress, growth factors, pro-inflammatory cytokines, in-
ducing genes regulating vSMC proliferation, migration and plasticity
[12].
4.4. The lncRNA MiR143HG: structure and functional importance
The lncRNA MiR143HG was first described in the literature by
Ouzain et al. as differential expressed during cardiovascular lineage
specification in cardiac precursor cells (CPCs) and proliferating cells
[66]. Computational analysis classified MiR143HG among the tran-
scripts lacking of any coding potential [67]. Moreover, ChiP-Seq ana-
lysis of human foetal and adult heart associated the transcript with an
active cardiac enhancer [68]. Therefore, the lncRNA MiR143HG was
named Cardiac Mesoderm Enhancer-associated Noncoding RNA
(CARMN). For simplicity, here we will refer to the lncRNA as
Fig. 2. Regulatory networks controlled by miR-143/145 in cardiovascular de-
velopment and disease in vSMCs.
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MiR143HG. MiR143HG belongs to the intergenic lncRNA group of
ncRNAs with multi-exonic spliced variants. Publicly available datasets
report the expression of MiR143HG mostly in the nucleus of different
cell lines and organs [69] indicating the potential wide involvement of
this lncRNA in different physiological contexts. Moreover, the genomic
annotation in Ensembl includes 12 noncoding human transcripts gen-
erated by the MiR143HG locus, which have been recently confirmed by
the RNA Capture Long-read Sequencing technique [70](Fig. 3). How-
ever, the potentially incomplete nature of data in the lncRNA annota-
tion may ultimately lead to further updates to the annotation, which
might especially true for variants that are rare. Importantly, the pro-
moter region of MiR143HG shows evolutionary conservation across
species (gene annotation set from GENCODE version 27), suggesting a
potential conservation of the transcriptional regulation. Similarly to the
human locus, murine MiR143HG is the host gene for the miR-143/145
cluster and yields two MiR143HG splice variants (mouse genome as-
sembly GRCm38) (Fig. 3). Interestingly, analysis of chromatin for en-
hancer-associated noncoding RNA showed that MiR143HG may be
implicated in the regulation of chromatin state activation and en-
hancer-like signature [71] suggesting a cis-acting function in cardiac
differentiation.
4.5. LncRNA MiR143HG in the pathophysiology of disease
Importantly, MiR143HG is expressed not only during cardiac dif-
ferentiation, but also in the adult mouse and human heart [72]. Parti-
cularly, Ouzain et al. described high expression of three of the twelve
human isoforms in CPCs versus proliferating cells using bioinformatics
and qPCR. Interestingly, the two downstream microRNAs, miR-143 and
miR-145, were found to have opposite expression patterns from the
lncRNA during cardiogenesis, thus indicating possible feedback me-
chanisms relating to transcript expression. Bioinformatic analysis
conducted by super enhancer track and ChIP-analysis revealed that the
lncRNA transcripts mapped to a cardiac enhancer, suggesting a role in
cardiac specification and differentiation. Consistent with this observa-
tion, analysis on chromatin state revealed an active super-enhancer
signature during cardiogenic differentiation between mesoderm and
CPC, in which the expression of MiR143HG isoforms was found to be
upregulated [50]. Furthermore, MiR143HG was also found to be highly
expressed in mouse CPC, indicating a potential role during the differ-
entiation of mouse ES. In vitro experiments in mouse and human foetal
CPCs, showed that the depletion of MiR143HG expression by shRNAi or
a GapmeR was associated with a significant reduction of cardiac dif-
ferentiation markers, impairing CPC differentiation [66]. Aside from a
role in physiology, the same research group demonstrated that
MiR143HG expression was also influenced by cardiac stress in a murine
model of myocardial infarction, where the two mouse transcripts were
found upregulated. Moreover, the lncRNA was shown to be upregulated
during cardiac remodelling in patients affected by aortic stenosis [66],
thus suggesting its potential role during the response to the pathological
remodelling in human and mouse heart. The lncRNA was also was
described to be involved in the differentiation of CPC into cardiomyo-
cytes or smooth muscle lineage being targeted by NOTCH signalling
[73]. Plaisance et al. observed an increase of MiR143HG expression in
CPC producing smooth muscle cells, were the microRNA cluster was
found to be expressed at high levels suggesting a positive co-regulation
of the two ncRNAs. In agreement with these results, the gapmeR-
mediated knock-out of MiR143HG induced a significant down-
regulation of miR-143 and miR-145 and a specification of CPCs toward
the cardiomyocyte commitment. Importantly, it was demonstrated that
MiR143HG and miR-143/145 are involved in a complex molecular
circuit regulating CPC differentiation into SMC. NOTCH activates
MiR143HG, a proximal enhancer element upstream of miR-143 and
miR-145, which in turns modulate the miR143/145 cluster, thus
Fig. 3. Schematic representation of human MiR143HG (Chr5 q32) and mouse (Chr18 E1) splice variants and pre-miRNA 143/145. The MiR143HG locus encodes for
twelve lncRNA isoforms in human and two in mouse.
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inducing smooth muscle differentiation genes [73].
5. Conclusions
NcRNAs can regulate gene expression at different levels, i.e. tran-
scriptionally, post-transcriptionally and post-translationally; and reg-
ulate various types of cell function(s): differentiation, metabolism, and
stress-responses [3]. MiR-143 and miR-145 have been well char-
acterised as crucial modulators of vSMC physiology, being central in the
regulation of complex molecular networks modulating vSMC pro-
liferation, migration, apoptosis and a phenotypic switch [46,51,61,74].
Importantly, dysregulated expression was associated with the devel-
opment of cardiovascular diseases [10,11,13]. More recently, in-
creasing evidence supports a critical function for lncRNA in the reg-
ulation of pathophysiological processes in the cardiovascular system
development and the progression of cardiovascular disease [36,75,76].
MiR143HG, host gene for miR-143 and miR145 and uncommonly well
conserved across species, was described to be important during cardiac
development and to be dysregulated under pathological conditions in
cardiomyocytes [66,73]. Recent studies have investigated the extensive
network of interactions between ncRNAs, microRNAs and lncRNA,
forming crucial regulatory axis involved in the modulation of cell
function [7,8]. MiR143HG and miR-143/145 represent a significant
example of a lncRNA/microRNA axis involved in the regulation of
vSMC function [77]. However, the mechanism of action by which this
lncRNA axis may regulate cellular processes still remains unclear.
Certainly, further investigations are required to identify the causal
mechanism that governs the phenotypic effects observed in vitro and in
vivo. The genetic ablation of MiR143HG in an animal model would
represent a comprehensive tool to elucidate the functional consequence
of MiR143HG loss in the development in early life and progression of
cardiovascular diseases in the adult. It is necessary to mechanistically
dissect the lncRNA/microRNA axis by separately modulating the ex-
pression of the three ncRNAs through targeted disruption of the axis.
Given the high level of complexity of the MiR143HG locus, which
suggests the essential role and interplay of MiR143HG-miR143/145
axis, additional investigation is required to clearly define their mole-
cular interactions and their functional role in cardiovascular disease
development and progression.
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